medi1341
mAbexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 17, 2017 (NCT03272165)
Timeline
Indications
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05526391 | Phase 2 | Nov 9, 2022 | AstraZeneca, Takeda |
| NCT04449484 | Phase 1 | Aug 4, 2020 | AstraZeneca |
| NCT03272165 | Phase 1 | Oct 17, 2017 | AstraZeneca, Catalent, Covance, MMS Holdings, Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 2 | 2 | 2017 |
| Catalent | For profit | 1 | 0 | 1 | 2017 |
| Covance | For profit | 1 | 0 | 1 | 2017 |
| MMS Holdings, Inc | For profit | 1 | 0 | 1 | 2017 |
| Takeda | For profit | 1 | 1 | 1 | 2022 |
5 organizations
Page 1 / 1